An In-vitro evaluation of a polyherbal formulation, against SARS-CoV-2

Kanchibhotla, Divya; Subramanian, Saumya; reddy, Ravi; Venkatesh, K R Hari; Pathania, Monika

doi:10.21203/rs.3.rs-936472/v1

Cited by 3 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies on the same formulation NOQ19 have shown promising results with respect to rate of recovery and antiviral e cacy [23][24][25] . A review of Ayurvedic literature presents robust preclinical evidence for e cacy of multiple NOQ19 ingredients such as Ashwagandha (Withania somnifera) and Guduchi (Tinospora cordifolia), along with Amalaki (Phyllanthus emblica) in proliferation of B and T cells and activation of nonspeci c immunity 32 .…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial.

Bhardwaja

Ganapathy

Pathania

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundTraditional medicine systems such as Ayurveda contain a vast repository of naturally occurring herbs with strong antimicrobial potency. A multitude of complementary therapies have been explored for their therapeutic role to treat COVID-19 during the pandemic. There have been promising results reported from in silico, in vitro and in vivo studies that need to be further explored in humans.ObjectiveThe present randomized placebo control trial evaluates the clinical efficacy of an integrated approach including Ayurvedic polyherbal formulation, NOQ19 in the improvement of mild to moderate category of COVID-19 infected patients.Patients and methodsA multicentric, randomized, placebo control design was adopted for the study. A total of 76 patients with positive COVID-19 RT-PCR test were enrolled in the study; 39 in the NOQ19 arm and 37 in the placebo arm. Patients were randomized and blinded to their respective intervention, which was provided along with the standard of care treatment. Rate of recovery assessment was done on Day 3, 5 and 7 via RT-PCR test to measure the rate of recovery. Blood markers were analysed on Day 0 and Day 7.OutcomesThe patients were assessed for rate of recovery via RT-PCR and improvement in blood biomarkers. They were also monitored for any adverse events or side effects of the drug.ResultsThe present study demonstrated a significant early recovery in the patients who took the NOQ19 formulation. Patients who received NOQ19 with the standard care of treatment showed clinical improvement in terms of oxygen requirement, breathlessness and SpO2, though the difference was not statistically significant. Moreover, no side effects were observed with the use of NOQ19.ConclusionAn overall integrated approach of standard of care treatment with Ayurvedic formulation (NOQ19) results in early clinical outcome in the management of mild to moderate cases of COVID-19.

show abstract

Section: Discussionmentioning

confidence: 98%

“…A previous in vitro study conducted on NOQ19 demonstrated its antiviral e cacy among Vero E6 SARS-CoV-2 infected cell lines. The treatment of virus infected cells with 0.9mg/ml concentration of NOQ19 resulted in a 100% viral elimination 23 . The NOQ19 was further tested in the Syrian golden hamsters animal model.…”

Section: Introductionmentioning

confidence: 99%

An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial.

Bhardwaja

Ganapathy

Pathania

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…[31] An Ayurvedic formulation, NOQ19 which contained W. somnifera herb displayed potent antiviral activity against SARS-CoV-2 in Vero E6 cell lines. [56] -…”

Section: Withania Somniferamentioning

confidence: 99%

“…[56] In addition, it has been proven to inhibit viral replication of various types of viruses including the influenza virus. [56] Among the various phytochem-icals, the immunomodulatory effect of cordifolioside A was stronger than berberine due to its interaction with TGF-β and TNF-α receptors. [81] Although its binding affinity to Mpro was quite low, cordifolioside A has high potential in modulating the cytokine storm event in Covid-19 patients.…”

Section: Regulation Of Mpro and Cytokine Stormmentioning

confidence: 99%

The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm

Choe

Yong

2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

Selected traditional medicinal plants exhibit therapeutic effects in coronavirus disease (Covid‐19) patients. This review aims to identify the phytochemicals from five traditional medicinal plants (Glycyrrhiza glabra, Nigella sativa, Curcuma longa, Tinospora cordifolia and Withania somnifera) with high potential in modulating the main protease (Mpro) activity and cytokine storm in Covid‐19 infection. The Mpro binding affinity of 13 plant phytochemicals were in the following order: Withanoside II > withanoside IV > withaferin A > α‐hederin > withanoside V > sitoindoside IX > glabridin > liquiritigenin, nigellidine > curcumin > glycyrrhizin > tinocordiside > berberine. Among these phytochemicals, glycyrrhizin, withaferin A, curcumin, nigellidine and cordifolioside A suppressed SARS‐CoV‐2 replication and showed stronger anti‐inflammatory activities than standard Covid‐19 drugs. Both pre‐clinical and clinical evidences supported the development of plant phytochemicals as Mpro inhibitors.

show abstract

“…Piperine plays an important role in inhibiting the entry of SARS-CoV-2 into the cell by increasing the curcumin and catechin in plasma. This role is attributed to the bioavailability enhancement property of piperine [24] . Previous in vitro studies on NF2 have shown 100% antiviral e cacy in a Vero E6 cell line-based assay [25] .…”

Section: Introductionmentioning

confidence: 99%

Ayurveda and Management of COVID-19 in Rural Indian Population: A pilot, double blind, randomized control trial

Chandra¹,

Subramanian²,

Wadhawan³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background The SARS-CoV-2 virus responsible for the COVID-19 pandemic is a highly contagious and rapidly mutating virus. The COVID-19 pandemic has affected millions globally over the last 18 months and continues to overwhelm the healthcare system in several countries to date. The healthcare and scientific community has been vigorously searching for ways to manage the disease. Several solutions based on traditional systems of medicine like Ayurveda are also being explored for their effectiveness in managing COVID-19. The study explored the efficacy of a 19 ingredient Ayurvedic polyherbal formulation called NOQ19, on the recovery of mild, RT-PCR positive COVID-19 patients. Methods This was a prospective, double blind, randomized control trial that included 92 patients with a RT-PCR positive mild case of COVID-19. The patients were enrolled from rural areas of Karnataka, a state in India. The patients were randomized between the NF2 and placebo arms, in a 1:1 ratio, and were provided their respective intervention, along with the standard of care treatment (SOC). The trial took place at the Community Care Center, Konnanuru, Hassan, Karnataka. The study duration was around 2 months and the follow-up period for an individual patient was 14 days. RT-PCR analysis was done at baseline, Day 3, 7 and 10. Blood markers to track inflammation were assessed at baseline, Day 3 and 7. Result A statistically significant difference was observed between the two groups with regards to the percentage of population who turned RT-PCR negative on Day 3 and Day 10. On all three assessment time points (Day 3, 7 and 10), the NF2+SOC arm showed a greater percentage of population who were RT-PCR negative compared to the placebo+SOC arm: Day 3 (NF2 -19%, Placebo - 0%) ; Day 7 (NF2- 41%, Placebo - 19%) ; Day 10 (NF2-73%, Placebo 44%). No significant changes were observed in blood markers for both the groups. Conclusion NF2 administered along with standard of care treatment aided early recovery from COVID-19 as demonstrated by a higher percentage of population who were RT-PCR negative on Day 3, 7 and 10. No side effects were observed during the entire study duration. Early recovery of patients is essential for rational usage of limited healthcare resources in a pandemic.

show abstract

An In-vitro evaluation of a polyherbal formulation, against SARS-CoV-2

Cited by 3 publications

References 11 publications

An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial.

An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial.

The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm

Ayurveda and Management of COVID-19 in Rural Indian Population: A pilot, double blind, randomized control trial

Contact Info

Product

Resources

About